Pharma-Bio Serv, Inc. (PBSV) Financial Statements (2023 and earlier)

Company Profile

Business Address INDUSTRIAL ZONE STREET 1
DORADO, 00646
State of Incorp.
Fiscal Year End October 31
Industry (SIC) 8742 - Management Consulting Services (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
10/31/2021
Q4
7/31/2021
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14,46314,23913,16415,352 16,498
Cash and cash equivalents14,46314,23913,16415,352 16,498
Receivables4,9834,8035,4785,046 10,082
Other undisclosed current assets498543508624 819
Total current assets:19,94419,58519,15021,022 27,399
Noncurrent Assets
Operating lease, right-of-use asset503539573606 722
Property, plant and equipment74748593 121
Other noncurrent assets131 353353 353
Other undisclosed noncurrent assets 131    
Total noncurrent assets:7077441,0111,053 1,196
TOTAL ASSETS:20,65120,32920,16122,074 28,595
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,6301,7391,5121,690 1,811
Accounts payable 1,7391,512   
Taxes payable   1,851 1,851
Other undisclosed accounts payable and accrued liabilities1,630  (161) (40)
Other undisclosed current liabilities478420679632 550
Total current liabilities:2,1082,1582,1912,322 2,361
Noncurrent Liabilities
Long-term debt and lease obligation347383418453 524
Operating lease, liability347383418453 524
Other undisclosed noncurrent liabilities1,2931,2561,2391,415 1,345
Total noncurrent liabilities:1,6392,0222,0752,322 2,392
Total liabilities:4,0934,1804,2674,644 4,754
Stockholders' equity
Stockholders' equity attributable to parent16,55816,14915,89517,431 23,841
Common stock2222 2
Treasury stock, value(502)(500)(491)(475) (394)
Additional paid in capital1,5521,5231,5091,495 1,458
Accumulated other comprehensive income2382968119 194
Retained earnings15,26715,09414,80616,290 22,580
Total stockholders' equity:16,55816,14915,89517,431 23,841
TOTAL LIABILITIES AND EQUITY:20,65120,32920,16122,074 28,595

Income Statement (P&L) ($ in thousands)

10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
10/31/2021
Q4
7/31/2021
Q3
Revenues4,6384,7744,9675,019 4,988
Cost of revenue(3,530)(3,462)(3,751)(3,775) (3,733)
Gross profit:1,1091,3121,2161,245 1,255
Operating expenses(940)(943)(935)(889) (895)
Operating income:169370281356 360
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
62(54)41 1,953
Income from continuing operations before income taxes:231316285356 2,313
Income tax expense(58)(28)(45)(51) (38)
Net income available to common stockholders, diluted:173288240305 2,275

Comprehensive Income ($ in thousands)

10/31/2022
Q4
7/31/2022
Q3
4/30/2022
Q2
1/31/2022
Q1
10/31/2021
Q4
7/31/2021
Q3
Net income:173288240305 2,275
Comprehensive income:173288240305 2,275
Other undisclosed comprehensive income (loss), net of tax, attributable to parent210(39)(51)(25) 5
Comprehensive income, net of tax, attributable to parent:383249189280 2,280

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: